Pharmacy News

Today's Pharmaceutical and Pharmacy News

Daily News Topic:

FDA News

5/24/13 - FDA Clears Masimo rainbowÂ® Acoustic Monitoring Sensor for Use on Pediatric Patients

By a News Reporter-Staff News Editor at Health& Medicine Week-- Masimo announced that its rainbow Acoustic Monitoringâ?¢ sensor, RAS-125c Acoustic Respiration Cloth Sensor has received U.S. FDA 510 clearance for continuous, noninvasive monitoring of acoustic respiration rate in pediatric patients. Masimo rainbow Acoustic Monitoring noninvasively an

5/24/13 - Omeros Announces INDA for OMS824 Cleared by FDA; Celgene Announces FDA Grants Priority Review for ABRAXANE

Below is a look at some of the headlines for companies that made news in the healthcare sector on May 23, 2013.{ nfg} Omeros Corporation announced its Investigational New Drug Application to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Omeros plans to advance OMS824 into Phase 2 clinical trials for Huntington's disease next

5/24/13 - Perosphere Gets FDA IND Clearance to Initiate Clinical Investigations of the Safety and Efficacy of PER977 to Reverse the Activity of Anticoagulation... [Health & Beauty Close - Up]

Perosphere Inc. said that it has received U.S. Food and Drug Administration Investigational New Drug clearance to initiate clinical investigations of the safety and efficacy of PER977 to reverse the anticoagulant activity of unfractionated heparin, low molecular weight heparins, fondaparinux, and factor Xa- and IIa-inhibitors. Daiichi Sankyo Compan

5/23/13 - Celgene Announces FDA Grants Priority Review for ABRAXANE sNDA in Advanced Pancreatic Cancer

Celgene International SÃ rl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE^ Â® in combination with gemcitabine for the firstâ?? line treatment of patients with advanced pancreatic cancer.

5/23/13 - Celgene Announces U.S. FDA Grants Priority Review for ABRAXANEÂ® sNDA in Advanced Pancreatic Cancer

BOUDRY, Switzerland---- Celgene International SÃ rl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE Â® in combination with gemcitabine for the firstâ?? line treatment of patients with advanced p

5/23/13 - Covidien Wins FDA 510(k) Clearance for Nellcor Pulse Oximetry Motion Claims [Health & Beauty Close - Up]

Covidien, a global provider of healthcare, announced that its Nellcor pulse oximetry portfolio, which is used to measure arterial oxygen saturation, has received U.S. Food and Drug Administration 510 clearance for motion claims. According to a release, this makes Covidien the first company to receive FDA clearance for a motion-tolerant bedside puls

Chain Drug Review

Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.

Featured Article from Chain Drug Review:

AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more